Evidence map›Paper›PMID 41737588›Full record

ReviewFrontiers in transplantation2026

Innovative approaches targeting innate immune cells to promote organ transplant tolerance.

Chiyoshi Toyama, Angus W Thomson

Abstract readReview
In one paragraph

Review in Frontiers in transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chiyoshi ToyamaDepartment of Surgery, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, United States.
Angus W ThomsonDepartment of Surgery, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, United States.

Funding

Transplant Pathology and Tissue Imaging Core BP01AI181829 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Angus W Thomson · 2025 to 2026
$5.7M
Innovative approaches to enhance regulatory myeloid cell function and renal transplant survival in nonhuman primatesR01AI184406 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THOMSON, ANGUS W · 2024 to 2024
$804k
NIAID NIH HHS P01 AI181829NIAID NIH HHS R01 AI184406
6 · The paper itself

Abstract

Achieving long-term allograft survival while minimizing systemic immunosuppression (IS) remains a critical unmet need in transplantation. While adaptive immunity has traditionally been the primary focus of IS therapy, innate immune cells-that include neutrophils, monocytes, macrophages, dendritic cells, myeloid-derived suppressor cells, innate lymphoid cells (ILCs), natural killer (NK) cells, and gamma delta (γδ) T cells act as key upstream orchestrators of allograft rejection and tolerance. Recent advances in single-cell RNA sequencing and spatial transcriptomics have unveiled the profound heterogeneity of these cell populations, identifying distinct regulatory subsets and novel inhibitory checkpoints. These high-resolution insights provide the scientific rationale for developing innovative precision therapies that can selectively modulate innate immune reactivity without compromising global immunity. Here, we review innovative strategies to target/amplify these mechanisms, including targeting the myeloid inhibitory checkpoints (e.g., leukocyte immunoglobulin-like receptor B; sialic acid-binding immunoglobulin-like lectin-E) to induce tolerogenic phenotypes. We further discuss the modulation of metabolic reprogramming to prevent "trained immunity" using mammalian target of rapamycin inhibitor (mTORi)-loaded nanoparticles, and the use of CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 gene editing to silence T cell costimulatory signals. We evaluate the adoptive transfer of regulatory myeloid cells, -specifically donor-derived regulatory macrophages and regulatory dendritic cells, and innate lymphoid cells in transplant recipients. Furthermore, the potential of targeting specific NK cell and ILC subsets associated with graft regulation is addressed. Collectively, these emerging approaches aim to reprogram the allograft microenvironment, offering a promising paradigm shift towards establishing transplant tolerance.

Indexed as

dendritic cellsimmunotherapyinnate lymphoid cellsmacrophagesmonocytesmyeloid cellsmyeloid-derived suppressor cellsnatural killer cells

Identifiers

PMID41737588
PMCPMC12926429

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.